Temporomandibular joint disorders (TMDs) usually present with symptoms and signs such as pain, mandibular movement, dysfunction, or joint sounds.
Introduction
There are different signs and symptoms indicating temporomandibular joint disorder (TMD) among which are the temporomandibular joint (TMJ) pain, mandibular movement dysfunction, and joint sounds (click or crepitus). One of the most prevalent findings in TMD patients is articular disc displacement that is the most significant cause of joint click sound. [1] [2] Lateral pterygoid muscle (LP) is one of the four pairs of masticatory muscles. It acts as a fundamental element in horizontal movements of the condyle. [3] Since this muscle attaches to the joint capsule and possibly the articular disc, [4] [5] the relationship between LP dysfunction and TMDs such as anterior displacement of the disc is taken into consideration. [6] [7] Accordingly, if changes in normal activities of LP is the main cause of TMDs, treatment of the individual muscle becomes necessary.
Different conservative treatments namely warm compresses, behavioral therapy, oral appliances, and drugs (such as anti-inflammatories and muscle relaxant-s), as well as low-level laser therapy are used to Regarding the fact that pain is the main manifes- 
Searching Strategy
The selected online databases including Scopus, Medline, Cochrane, EMBASE, and Ebsco were searched for the keywords "pterygoid muscle" and "onabotuli- Three of these articles [8, [16] [17] were "narrative review", all the references of which were included in the present study (within the scope of the present study); thus, those three articles were not entailed in we included only the complete report. [19] The quality of clinical trials was assessed by CONSORT checklist 2010. Accordingly, if the study met any of the CONSORT items, it was scored as 1, and in case of non-compliance, it was scored as 0 for that item; thus the CONSORT score for each study ranged from a minimum of 0 to the maximum of 37 (Table 1) .
Data extracted from the 24 articles included the study title, name of the author(s), date of publication, type of the study, the underlying disorders, BTX-A dosage, site of injection, frequency of administration, and treatment outcomes, as well as the possible treatment side effects.
Out of the 24 articles included, 4 were interventional (experimental) studies (Table 1) . Generally, all of these studies had reported satisfactory results for the injection of botulinum in the study groups compared with the control groups. Although in some of these studies comparison of some variables between the intervention and the control group had no statistically significant difference, an overall assessment clearly revealed that injection of botulinum toxin in the LP muscle reduced pain, click sound, mandibular deviations in jaw movements, and muscle dysfunction compared with the control group. Table 2 displays more details on the four above-mentioned studies.
Twenty articles were case-report, case series, and retrospective studies as demonstrated in detail in Table   3 .
Discussion
Botulinum toxin type A is a paralytic neurotoxin whose main function is to inhibit acetylcholine release at the neuromuscular junction. The U.S. FDA has approved the use of BTX-A in treating belpharospasm, strabismus, hemifacial spasm, cervical dystonia, glabellar lines, and hyperhidrosis. BTX-A is also safely employed in treating hyperfunctional facial lines, other dystonias, spasticity, and head and neck tremor. [8] However, FDA has not firmly approved BTX-A for treatment of masticatory muscles spasm yet, which might be due to the lack of adequate researches on the issue. [3] Injection of BTX-A in maxillofacial muscles for treatment of pain, tonicity change, and improving the symptoms of TMD has been already considered as a treatment modality by researchers. [13, [16] [17] Although, no study has shown the priority of more conservative treatments such as warm and cold compression, splint therapy, physiotherapy, and so on over botulinum injection for the TMD symptoms, conservative methods should be considered as the first treatment line due to the invasiveness of injection. [2, 20] According to the trend of the current study on the use of botulinum toxin in LP muscle, most researchers Table 2 .
For many years, BTX-A has been used to treat the hyperactivity of LP muscle. In an evidence-based review, Ihde et al. [17] evaluated the therapeutic effect of botulinum on relieving chronic facial pain. They noticed adverse effects such as muscle paralysis and dysphagia in a number of patients. It was described as the temporary symptom, and recovered after a short time. They also pointed out that four weeks after beginning the treatment, about 91% of patients expressed improvement in facial pain.
[17]
Song et al. [8] investigated the effects of botulinum toxin on the treatment of TMD. They aimed to collect and define a specific algorithm for treatment of TMD patients. They announced that conservative treatments such as warm compresses, behavioral therapy, oral appliances, and drugs (like anti-inflammatories and muscle relaxants) were prior to BTX-A injection. [8] Hence, toxin was recommended for patients who would not respond to conservative treatments. They also deduced a recommended dose of BTX-A in treatment of TMD patients, which was 7.5-10 of the standard unit for LP muscle, prescribed in case of sub-maxillary pain, jaw deviation, or habits such as bruxism. [8] Emara et al. [2] assessed the effects of botulinum toxin in LP muscle for the treatment of joint click in 6 patients (11 involved joints). The electromyogram (EMG) was used to define the proper insertion site of injection. They observed that toxin injection eliminated the click sound in 10 joints during the first week and in one joint after a week. During three to four following months, recurrence of click sound was reported in only one joint. [2] Later, von Lindren [21] evaluated the effect of botulinum toxin injections on reducing the maxillofacial muscle pain associated with TMJ dysfunction.
EMG was employed during injection in muscles that were difficult to access including the lateral pterygoid muscle (8 out of 41 patients). Accordingly, localized pain was recovered in 80% of patients and remained in about half of the patients for 3 months after injection.
[21]
The injection method
Due to the more difficult access to LP muscle compared with other masticatory muscles, EMG was used to determine the exact place of needle entrance. According to EMG guidance to LP, the needle may insert extra-orally anterior to the condylar neck with 45°
angle. In cases of intra-oral access, the injection site would be posterior to the maxillary tuberosity with 45°
angle. [2, [18] [19] 
Frequency of injections
In three of the experimental studies [2, 20, 22] a single injection was administered; and in one study, [21] 17% of patients received a second injection. Generally in these studies, the impact of single dose normally last until the end of the follow-up period. In all investigated cases, the first dose yielded relatively favorable outcomes and repeated doses after 2-6 months were performed to strengthen the effect of previous injection. The frequency of booster dose injection varied among the reported cases (Table 3) .
Dose of injection
In the experimental studies, [2, [20] [21] [22] a dose of 12.5 to 200 units per muscle was used. Different case reports mentioned various injection doses (Table 3) .
With respect to the desired treatment outcome and lack of comparison with other studies, the administered dose and any definitive guideline which was used were not challenged. In an overview, it seems that researchers used proper doses of injection based on the severity of involvement; for instance, the maximum dose (150 units per muscle) was used for bruxism subsequent to cerebral palsy, [23] airway collapse caused by jaw dislocation associated with muscle dystonia, [24] and recurrent dislocation of the jaw. [25] Adverse effects of injection
The previously reported adverse effects such as belph-aroptosis, brow ptosis, and diplopia at the site of injection which were seen in the treatment of headache disorders were not matters of issue in the present research. [26] In the experimental studies, [2, [20] [21] [22] the side effects of injection were often mild or transient and were reported in quite a few percent of the patients. The majority of these studies reported only temporary unwanted symptoms such as dysphagia, difficulty in articulation, muscle weakness, transient speech disorder, and flu-like symptoms. [8] In other reviewed articles, no side effect was observed except for the temporary mild dysphagia (Table 3 ). There were also minor complications associated with needle injections such as bruising and local tenderness. [8] Since none of the interventional studies reported any evidence to avoid the toxin injection in the maxillofacial muscles, the temporary problems may not be a contraindication to the use of this toxin as a treatment modality for TMD. 
Conclusion

